Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | PNMT | P11086 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 2/20 | 0.33 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7571188 | 0.81 | ADRA1D (0.35) | GABRA1GABRB2PNMTHTR1AADRA1D | |
| SCHEMBL5136508 | 0.75 | ADRA2A (0.38) | ADRA2AADRA2BADRA2C | |
| SCHEMBL6404951 | 0.73 | THRA (0.36) | — | |
| SCHEMBL8509648 | 0.70 | GABRA1 (0.49) | GABRA1GABRB2AKR1B1PNMTHTR1A | |
| SCHEMBL5824091 | 0.69 | GABRA1 (0.58) | GABRA1GABRB2AKR1B1ADRA2AADRA2B | |
| SCHEMBL7166791 | 0.69 | CYP3A4 (0.30) | — | |
| SCHEMBL6536949 | 0.69 | GABRA1 (0.35) | GABRA1GABRB2AKR1B1 | |
| SCHEMBL5859274 | 0.67 | ACHE (0.45) | HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL252161 | 0.67 | PNMT (0.62) | GABRA1GABRB2AKR1B1PNMTHTR1A | |
| SCHEMBL14262138 | 0.67 | GABRA1 (0.49) | GABRA1GABRB2AKR1B1ADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040267072-A1 | Cross-coupling synthesis of alkyl (dialkylphenyl) indenes | ANTARES CAPITAL LP, AS AGENT | 2004-12-30 | — | — | US | claimed |
| US-6291699-B1 | TO PRODUCE BRIDGED METALLOCENE LIGANDS WHICH CAN BE CONVERTED INTO BRIDGED METALLOCENES USEFUL AS OLFIN POLYMERIZATION CATALYST | BOULDER SCIENTIFIC COMPANY | 2001-09-18 | — | — | US | claimed |
| EP-1572606-A4 | CROSS-COUPLING SYNTHESIS OF ALKYL (DIALKYLPHENYL) INDENES | BOULDER SCIENT CO (US) | 2008-07-09 | — | — | EP | disclosed |
| EP-1572606-A4 | CROSS-COUPLING SYNTHESIS OF ALKYL (DIALKYLPHENYL) INDENES | BOULDER SCIENT CO (US) | 2008-07-09 | — | — | EP | disclosed |
| US-7205427-B2 | Cross-coupling synthesis of alkyl (dialkylphenyl) indenes | BOULDER SCIENTIFIC COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
| US-7205427-B2 | Cross-coupling synthesis of alkyl (dialkylphenyl) indenes | BOULDER SCIENTIFIC COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
| EP-1572606-A2 | CROSS-COUPLING SYNTHESIS OF ALKYL (DIALKYLPHENYL) INDENES | BOULDER SCIENTIFIC COMPANY (US) | 2005-09-14 | — | — | EP | disclosed |
| EP-1572606-A2 | CROSS-COUPLING SYNTHESIS OF ALKYL (DIALKYLPHENYL) INDENES | BOULDER SCIENTIFIC COMPANY (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20040267072-A1 | Cross-coupling synthesis of alkyl (dialkylphenyl) indenes | ANTARES CAPITAL LP, AS AGENT | 2004-12-30 | — | — | US | disclosed |
| US-20040267072-A1 | Cross-coupling synthesis of alkyl (dialkylphenyl) indenes | ANTARES CAPITAL LP, AS AGENT | 2004-12-30 | — | — | US | disclosed |
| WO-2003101601-A3 | CROSS-COUPLING SYNTHESIS OF ALKYL (DIALKYLPHENYL) INDENES | BOULDER SCIENT CO (US) | 2004-05-13 | — | — | WO | disclosed |
| US-6291699-B1 | TO PRODUCE BRIDGED METALLOCENE LIGANDS WHICH CAN BE CONVERTED INTO BRIDGED METALLOCENES USEFUL AS OLFIN POLYMERIZATION CATALYST | BOULDER SCIENTIFIC COMPANY | 2001-09-18 | — | — | US | disclosed |
| US-6291699-B1 | TO PRODUCE BRIDGED METALLOCENE LIGANDS WHICH CAN BE CONVERTED INTO BRIDGED METALLOCENES USEFUL AS OLFIN POLYMERIZATION CATALYST | BOULDER SCIENTIFIC COMPANY | 2001-09-18 | — | — | US | disclosed |
| EP-1123298-A1 | 2-ALKYL-4-(2,6-DIALKYLPHENYL) INDENES | BOULDER SCIENTIFIC COMPANY (US) | 2001-08-16 | — | — | EP | disclosed |
| EP-1123298-A1 | 2-ALKYL-4-(2,6-DIALKYLPHENYL) INDENES | BOULDER SCIENTIFIC COMPANY (US) | 2001-08-16 | — | — | EP | disclosed |
| EP-1123298-A1 | 2-ALKYL-4-(2,6-DIALKYLPHENYL) INDENES | BOULDER SCIENTIFIC COMPANY (US) | 2001-08-16 | — | — | EP | disclosed |
| WO-2001014388-A1 | 2-ALKYL-4-(2,6-DIALKYLPHENYL) INDENES | BOULDER SCIENTIFIC COMPANY (US) | 2001-03-01 | — | — | WO | disclosed |
| WO-2001014388-A1 | 2-ALKYL-4-(2,6-DIALKYLPHENYL) INDENES | BOULDER SCIENTIFIC COMPANY (US) | 2001-03-01 | — | — | WO | disclosed |
| WO-2001014388-A1 | 2-ALKYL-4-(2,6-DIALKYLPHENYL) INDENES | BOULDER SCIENTIFIC COMPANY (US) | 2001-03-01 | — | — | WO | disclosed |
| US-3914305-A | N-{8 (10,11-dihydro-5H-dibenzo{8 a,d{9 cyclohepten-5-yl)methyl{9 amides | AYERST MCKENNA & HARRISON | 1975-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040267072-A1 | Cross-coupling synthesis of alkyl (dialkylphenyl) indenes | DDT, DUOX2, DYRK4 | GABRA1 1204/4885GABRB2 976/4885AKR1B1 792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.